A Placebo Controlled, Parallel Group, Randomised Withdrawal Study of Subjects With Symptoms of Spasticity Due to Multiple Sclerosis Who Are Receiving Long-term Sativex.

Trial Profile

A Placebo Controlled, Parallel Group, Randomised Withdrawal Study of Subjects With Symptoms of Spasticity Due to Multiple Sclerosis Who Are Receiving Long-term Sativex.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2013

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Multiple sclerosis; Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 14 Oct 2010 According to an Almirall media release, results from 3 pivotal clinical studies of tetrahydrocannabinol/cannabidiol (Sativex) were presented in a satellite symposium at the 26th annual congress of the ECTRIMS.
    • 03 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Sep 2009 Results were presented at ECTRIMS 2009, according toa GW Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top